Until now there has been no test that could detect synacthen, which when injected simulates the body to produce extra amounts of its own corticosteroid. This is most common in sports where sports ...

Injecting performance enhancing corticosteroid hormones for other than medical treatment is banned, and tests exist that can detect injected hormones. Injecting synacthen, which stimulates the body to ...

Questcor Pharmaceuticals said today it acquired rights to develop Synacthen® (tetracosactide) and Synacthen Depot in the U.S. from Novartis Pharma and parent company Novartis, in a deal that could net ...

This leaflet answers some common questions about Synacthen Depot. It does not contain all the available information. It does not take the place of talking to your doctor or pharmacist. All medicines ...

Shares of Questcor Pharmaceuticals, Inc. (QCOR) recently received a major boost when the company announced the acquisition of development and commercialization rights to Synacthen and Synacthen Depot ...

Mallinckrodt plc (NYSE: MNK) revealed Monday that it submitted an Investigational New Drug (IND) application for Synacthen Depot to the U.S. Food and Drug Administration (FDA). The company indicated ...

Why try to beat 'em if you can just buy 'em? That's the approach that Questcor Pharmaceuticals is taking. The biotech announced today that it has acquired rights to develop Syncathen and Synacthen ...

Mallinckrodt Pharmaceuticals' agreed to pay $100 million to settle Federal Trade Commission (FTC) charges it used its monopoly on a lupus and multiple sclerosis drug, Acthar, to unfairly jack up its ...